Professional Background:
Yanling is a technical leader with strong expertise in biopharmecautical product development and manufacturing. She was initially trained as an applied chemist in China and later obtained her Master and PhD degrees in Physical Biochemistry in the UK. Prior to moving to Australia in 2009, she was a Senior Scientist in Bioprocess Development at MedImmune Cambridge UK (now AstraZeneca) leading antibody characterisation and formulation development. In the last 18 years, Yanling has led R&D teams in the biotech sector across UK, US and Australia. She has a track record of bringing discovery projects through development to commercialisation with her versatile skills and experiences covering drug discovery and development, assay development, process development & CMC, cGMP biomanufacturing, clinical trials and regulatory.
Research Interests:
Yanling is Head of Chemistry, Manufacturing and Control (CMC) at GlyTherix where they are developing radiopharmaceutical reagents for the treatment of solid tumours. Currently she manages all CMC programs including antibody manufacturing, bioconjugation and radiopharmaceutical drug manufacturing.
